A diverse group of researchers and diagnostic industry participants has collaborated to produce two papers that describe and critique Lyme disease testing technologies.
The firm is developing tests combining biomarkers and other clinical measures to diagnose and monitor patients and identify those at risk of long-term effects.
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.
Years after several high-profile failures, activity is up among researchers looking to multi-analyte protein assays for monitoring and detection of the disease.
Based on the level of 25 serum markers, the test is meant to assess risk of both spontaneous preterm delivery and deliveries indicated by an underlying condition.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The firm presented on its pancreatic, breast, and prostate cancer programs, the latter of which is moving through clinical validation toward commercialization.
Because of a statistical error in a recent study, the firm reduced test performance numbers, but it noted that the revised numbers are still far better than standard histopathology.
The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.
